Clinical Trial Update: VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM [Phase 3]

View source ↗

Summary

DelMar Pharmaceuticals' VAL-083 Phase 3 trial for recurrent glioblastoma (after temozolomide and bevacizumab) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• VAL-083 (dianhydrogalactitol)

Snippet

Sponsor: DelMar Pharmaceuticals, Inc. | Conditions: Glioblastoma Multiforme, Glioblastoma | Phase 3 | Status: TERMINATED